Astellas's antibody conjugate for renal cancer enters the clinic
This article was originally published in Scrip
Astellas's US-based anticancer antibody subsidiary, Agensys, has begun clinical trials with an antibody-drug conjugate (ADC) for metastatic renal cancer, building on an alliance with Seattle Genetics which was expanded last year.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.